Schizophrenia is a complex disorder, viewed as a collection of different disorders that develops over time.
Full psychosis represents later stages, since it's developmental nature
Early, intensive intervention may provide greater help and long-term benefits for people with schizophrenia
Cognitive symptoms go through various dysfunctions:
Poor information processing for decision-making
Impaired ability to focus on objectives
Abnormalities in working memory and learning
Difficulty retaining information
There is no therapies approved for cognitive symptoms right now.
Evaluate the effectiveness of the investigational
medication, Luvadaxistat, in individuals with schizophrenia.
Understand whether the investigational medication is safe, how the body handles taking it, and whether it works to improve cognitive function in study participants with schizophrenia.
Who May Qualify
Approximately 308 participants are expected to participate in the ERUDITE Study globally.
If you’re having trouble with memory or focus caused by schizophrenia.
Together We Can Contribute More to Important Research on Schizophrenia: Who Can Participate?
Have a confirmed diagnosis of schizophrenia at least 1 year prior to participating in the research study.
Have not have a lifetime diagnosis of schizoaffective disorder, bipolar disorder, or obsessive-compulsive disorder.
Are between 18 and 50 years of age (inclusive).
Have not had an occurrence of panic disorder or depression within the past 6 months.
Are not pregnant or breastfeeding.
Are already receiving antipsychotic therapy for schizophrenia.
Your time and effort will be financially compensated and you can withdraw at any time you want for any reason you want.
Download the ERUDITE material and take it with you:
Meet out other studies!
Evaluating the safety and efficacy of KarXT, an investigational drug, for the treatment of psychosis associated with Alzheimer’s disease dementia.
Asking if an investigational drug can improve cognition in people with schizophrenia
Evaluating an investigational medication for individuals with schizophrenia who have had an inadequate response to antipsychotic medication.